|
Michael S. Niederman, MD
Winthrop Titles/Positions
Chairman, Department of Medicine
Academic Faculty Appointments
Professor and Vice-Chairman, Department of Medicine, SUNY at Stony Brook
Address
222 Station Plaza N. Suite 509, Mineola, Ny 11501
Fax
516-663-8796
Email
mniederman@winthrop.org
Brief Resume
Dr. Niederman obtained his medical degree from Boston University School of Medicine, and then completed his training in internal medicine at Northwestern University School of Medicine, before undertaking a pulmonary and critical care fellowship at Yale University School of Medicine. His interests lie in respiratory tract infections, and include mechanisms of airway colonization, the management of community- and hospital-acquired pneumonia, the role of guidelines for pneumonia, and the impact of antibiotic resistance on the management and outcomes of respiratory tract infections. He has published over 350 peer reviewed or review articles, and has lectured widely, both nationally and internationally. Dr Niederman served as co-chairman of the committees that created the American Thoracic Society 1993 and 2001 guidelines for the treatment of community-acquired pneumonia and the 1996 and 2005 committees that wrote guidelines for the treatment of nosocomial pneumonia. He was a member of the ATS/IDSA committee that published guidelines for community-acquired pneumonia in 2007. He is also Editor-in-Chief of Clinical Pulmonary Medicine, and has served on the editorial boards of The American Journal of Respiratory and Critical Care Medicine, Critical Care Medicine, and Chest.
Description of Research Interests/Activities
Dr. Niederman's interest is focused on respiratory infections , specifically community- acquired pneumonia, nosocomial pneumonia, and healthcare associated pneumonia. Dr. Niederman has participated in clinical trials of new antimicrobial therapies for these illnesses and in clinical studies of the determinants of clinical outcomes for patients with respiratory infection. His studies have focused on developing and validating international guidelines for the management of community-acquired and nosocomial pneumonia. In these studies, the predictors of poor outcomes have been identified and the opportunities for improving outcomes such as length of stay and appropriate use of antibiotics , have been identified.
The focus of his current research is to define the proper approach to the management of healthcare associated pneumonia, and to define the role of adjunctive aerosolized antibiotics for patients with ventilator associated pneumonia. He is also interested in the use of serum biomarkers to define the proper duration of antibiotic therapy for patients with lung infiltrates. In addition, he is involved in the study of resource utilization in the ICU for patients defined to be receiving futile care.
Areas of Experience
Health Outcomes
Critical Care
Infections
Research Team Members
Veronica Britor
Shalinee Chawla
Clinical Practice and Interests
Pneumonia, respiratory failure, acute lung injury, exacerbations of COPD
Selected Publications
Fishbane S, Niederman MS, Daly C, Magin A, Kawabata M, de Corla- Souza A, Choudhery I, Brody G, Gaffney M, Pollack S, Parker S, “The Impact of standardized order sets and intensive clinical case management on outcomes in Community-Acquired Pneumonia”, Arch Intern Med 2007 Aug 13/27;167 (15);1664-1669
Valencia M, Badia JR, Cavalcanti M, Ferrer M, Agusti C, Angril J, Garcia E, Mensa J, Niederman MS, Torres, A, “Pneumonia Severity Index (PSI) Class v. Patients with Community-Acquired Pneumonia: Characteristics, Outcomes and value of severity Scores”, Chest 2007 Aug:132(2):515-522.
Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM Jr, Musher DM, Niederman MS, Torres A, Whitney CG, “Infectious Diseases Society of American/American Thoracic Society guidelines Committee for Community-Acquired Pneumonia “Clinical Infectious Dis. 2008 Oct. 15;47(8):1117-8.
Nair V, Niederman MS, Masani N, Fishbane S, “Hyponatremia in Community-Acquired Pneumonia”, American Journal of Nephrology, 2007;27(2):184-90
Kollef MH, Alfessa B, Anzueto A, Veremakis C, Kerr KM, Margolis BD,Craven DE, Roberts PR, Arroliga AC, Hubmayr RD, Restrepo MI Auger WR, Schinner R, Niederman, MS, NASCENT Investigation Group, JAMA 2008 Aug 20;300(7):805-13.
Kollef MH, Morrow, LE, Niederman MS, Leeper KV, Anzueto A, Benz-Scott L, Rodino FJ, “Clinical Characteristics and Treatment Patterns Among Patients with Ventilator-Associated Pneumonia”, Chest, May 2006, Vol 129(5):1117-1394
Pelosi P, Barassi A, Severgnini P, Gomiero B, Finazzi S, Merlini G, d’Eril, GM, Chiaranda M, Niederman MS, “Prognostic role of clinical and laboratory criteria to identify early VAP in Brain injury”, Chest, 2008 Jul;134(1):101-8
Dambrava PG, Torres A, Valles X, Mensa J, Marcos MA, Penarroja G, Camps, M, Estruch R, Sanchez M, Menendez R, Niederman MS, “Adherence to guidelines empiric antibiotic recommendations and CAP outcome”, European Respiratory Journal, 2008 Oct;32(4):892-901.
Maruyama T, Niederman MS, Kobayashi T, Kobayashi H, Takagi T, D’Alessandro-Gabazza CN, Fujimoto H, Gil Bernabe P, Hirohata S, Nakayama S, Nishikubo K, Yuda H, Yamaguchi A, Gabazza EC, Noguchi T, Takei Y, Taguchi O, “A prospective Comparison of nursing home-acquired pneumonia with hospital-acquired pneumonia in non-intubated elderly”, Respiratory Medicine 2008 Sep;102(9):1287-95
Niederman, MS, “Biological Markers to Determine Eligibility in Trials for Community-Acquired Pneumonia: A Focus on Procalcitonin”, Clinical Infectious Diseases 2008 Dec 1:47, (Suppl 3):S127-32.
Liapikou A, Ferrer M, Polverino E, Balasso V, Esperatti M, Piner R, Mensa J, Luque, N, Ewig S, Mendez R, Niederman M, Torres A, “Severe Community-Acquired Pneumonia: Validation of the Infectious Diseases Society of America/American Thoracic Society Guidelines to Predict an Intensive Care Unit Admission”, Clinical Infectious Diseases, Clinical Infectious Diseases, 2009, Feb. 15; 48(4):377-385.
Brito V, Niederman M, “Healthcare-associated pneumonia is a heterogeneous disease and all patients do not need the same broad-spectrum antibiotic therapy as complex nosocomial pneumonia,”Current Opinion in Infectious Diseases, 2009 June;22(3):316 – 325.
Niederman M, “In the clinic. Community-Acquired Pneumonia”, Annals of Internal Medicine, 2009 Oct 6;151(7), ITC4-2-ITC4-14;Quiz ITCA-16.
Maruyama T, Taguchi O, Niederman MS, Morser J, Kobayashi H, Kobayashi T, D'Alessandro-Gabazza C, Nakayama S, Nishikubo K, Noguchi T, Takei Y, Gabazza EC..Efficacy of 23-valent pneumococcal vaccine in preventing pneumonia and improving survival in nursing home residents: double blind, randomized and placebo controlled trial. BMJ 2010; 340:1149
Niederman, MS, “Making Sense of Scoring Systems in Community-Acquired Pneumonia”, Respirology, 2009 Apr;14(3), 327-335.
|
